Amgen, Cytokinetics and Servier announce atart of METEORIC-HF second phase 3 trial
Amgen, Cytokinetics, and Servier announced that METEORIC-HF (Multicenter Exercise Tolerance Evaluation of Omecamtiv Mecarbil Related to Increased Contractility in Heart Failure), the second Phase 3 clinical trial of omecamtiv mecarbil, a novel cardiac myosin activator, is open to enrollment. February 21, 2019